Cambridge, MA – December 3, 2025: Nona Biosciences has appointed Dr. Hongjiang Miao as its first Chief AI Officer, a strategic leadership move designed to accelerate the company’s A³ strategy—Antibody Engineering × AI × Automation—and formally position the organization as a next-generation AI-driven drug discovery enterprise. Dr. Miao, a computational biology and biocomputing expert, will oversee the development and integration of advanced AI workflows, platform evolution, and algorithmic innovation across the company’s global operations.
Science Significance
The appointment of Dr. Miao marks a critical scientific inflection point for Nona Biosciences as it deepens its use of AI-enhanced antibody discovery and preclinical design. His leadership in building high-precision 3D protein-structure prediction algorithms and pioneering AIGC-based protein design systems represents a transformative shift toward computationally guided therapeutics. Nona’s scientific strategy increasingly relies on data-rich modelling, automated experiment design, and deep integration of AI with antibody platforms, enabling faster target validation, optimized biologic engineering, and more predictive developability assessments. By embedding AI into its “I to I® (Idea to IND)” workflow, the company strengthens its ability to generate fully human monoclonal antibodies, heavy-chain-only antibodies, and next-generation multispecific formats with unprecedented efficiency.
Regulatory Significance
AI-enabled drug discovery is rapidly reshaping expectations for regulatory science, data integrity, and model validation, and Dr. Miao’s appointment signals Nona’s intent to operate at the forefront of these standards. The development of a unified AI R&D platform supports traceable digital workflows, enhances reproducibility, and improves the quality of data packages submitted during IND-stage regulatory interactions. As agencies increasingly evaluate algorithmic transparency, automated decision-making, and computational design tools in therapeutic development, Nona’s structured, platform-based approach provides a roadmap that aligns with emerging global regulatory guidance for AI in biologics development.
Business Significance
Advertisement
This leadership expansion strengthens Nona Biosciences’ competitiveness in the rapidly evolving biologics and computational drug discovery markets. By consolidating AI development under a dedicated executive, Nona positions itself to accelerate pipeline generation, partnership readiness, and platform scalability. The integration of Harbour Mice®, single-B-cell screening, and AI-driven design tools under a coordinated strategic vision enhances the company’s value proposition as a partner for global pharmaceutical and biotech firms seeking modalities-on-demand, CAR-T discovery platforms, antibody engineering, and IND-enabling research. With increasing industry demand for computational acceleration and automated biologics design, Nona’s A³ strategy represents a durable business differentiator that expands global client engagement and revenue potential.
Patients’ Significance
Patients stand to benefit from significantly shortened timelines between therapeutic concept and investigational candidate, particularly in areas requiring rapid innovation such as oncology, immunology, and complex biologic modalities. By unifying AI, automation, and antibody engineering, Nona aims to deliver more precise, better designed, and faster optimized therapeutic candidates, potentially reducing attrition rates and improving downstream safety and efficacy profiles. As biologics grow more sophisticated—bispecific antibodies, ADCs, VH single-domain antibodies, CAR-T constructs—AI-supported discovery platforms hold the potential to bring more personalized and structurally advanced medicines to patients sooner.
Policy Significance
The move reinforces global calls for integrating responsible AI practices into life sciences innovation, aligning with international initiatives encouraging modernization of discovery workflows, transparent computational methodologies, and scalable biotech innovation ecosystems. By formalizing a Chief AI Officer role, Nona signals compliance with principles surrounding algorithmic accountability, data quality governance, and automated system oversight, supporting future policy frameworks that will inevitably govern AI-enhanced therapeutic design at scale. This structural evolution will likely serve as a model for other biotechnology companies navigating emerging policy landscapes around AI in biomedical R&D.
Nona Biosciences’ appointment of Dr. Hongjiang Miao as Chief AI Officer underscores its commitment to transforming the biologics landscape through deep AI integration, automated precision workflows, and cutting-edge antibody engineering. As the company scales its A³ strategy, it stands poised to influence not only the science of drug discovery but also the regulatory, operational, and policy frameworks that will define the next generation of global biotherapeutics.
Source: Nona Biosciences press release
